The Medical Letter on Drugs and Therapeutics
Osmolex ER - Another Extended-Release Amantadine for Parkinson's Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved an extended-release tablet formulation of amantadine (Osmolex ER – Vertical/Osmotica) for once-daily treatment of Parkinson's disease (PD) and drug-induced extrapyramidal symptoms (EPS) in adults. An extended-release capsule formulation of amantadine (Gocovri) was approved in 2017 for treatment of levodopa-induced dyskinesia in patients with PD.1

STANDARD TREATMENT — Parkinson's Disease – The combination of levodopa and carbidopa is the most effective treatment for the motor symptoms of PD, but its long-term use leads to motor fluctuations and dyskinesia. Dopamine agonists such as pramipexole (Mirapex, and generics) and ropinirole (Requip, and generics) are less effective than levodopa; they can be used as monotherapy before the introduction of levodopa or as an adjunct to levodopa in patients with motor ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Osmolex ER - Another Extended-Release Amantadine for Parkinson's Disease
Article code: 1555c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian